Synonyms: ACE-536 | ACE536 | luspatercept-aamt | Reblozyl®
luspatercept is an approved drug (FDA (2019), EMA (2020))
Compound class:
Peptide or derivative
Comment: Luspatercept (ACE-536) is a fusion protein comprising human ACVR2B (activin receptor type 2B) extracellular domain (which is mutated to reduce activin binding), fused with human immunoglobulin G1 Fc fragment [2]. Mechanistically luspatercept acts as a ligand trap for growth/differentiation factor-11 (GDF11; and other Smad2/3-activating ligands), which reduces GDF11-induced Smad2/3 activation, and blocks the inhibitory effect of GDF11 on erythroid precursor maturation. Functionally, it promotes maturation of late-stage erythroid precursors, which is in contrast to erythropoietin, which stimulates proliferation of early-stage erythrocyte precursors. Using Gdf11 knockout, Guerra et al. (2019) dispute GDF11 as the molecular target of luspatercept and its proposed inhibitory effect on late erythropoiesis [1]. They do not propose an alternative mechanism of action.
|
For advanced searching click here to open chemical structure editor
Other Similar Sequences | |
rilonacept |
Targetsnull |
abatacept |
TargetsCD80; CD86 |
belatacept |
TargetsCD80; CD86 |
romiplostim |
TargetsThrombopoietin receptor |
trebananib |
Targetsnull |
resokine | |
efgartigimod alfa |
TargetsFc fragment of IgG receptor and transporter |
MK-7110 |
Targetssialic acid binding Ig like lectin 10 |
inbakicept | |
sotatercept |
Targetsnull |
efzofitimod |